
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is well-positioned to take advantage of the growing demand for alternative treatments to chronic corticosteroids and immunosuppressants for rare autoimmune diseases, with a focus on developing innovative antibody-based therapies. The company's recent FDA approvals for Vyvgart offer a convenient and effective treatment option, and its pipeline shows significant promise for addressing a range of rare autoimmune diseases. The company's strong management team and solid financials, including a projected multi-billion-dollar opportunity for their IMNM treatment, make argenx a promising investment choice for the future.
Bears say
argenx is experiencing success with FDA approvals for their leading product Vyvgart (efgartigimod) for the treatment of rare autoimmune diseases such as generalized myasthenia gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and now dermatomyositis (DM). However, the market for these diseases is relatively small, and conventional therapies still dominate treatment options for physicians. Therefore, the company may struggle with achieving significant revenue growth and maintaining a competitive edge in a highly saturated market.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares